Optimising assessments of the epidemiological impact in The Netherlands of paediatric immunisation with 13-valent pneumococcal conjugate vaccine using dynamic transmission modelling

Optimising assessments of the epidemiological impact in The Netherlands of paediatric immunisation with 13-valent pneumococcal conjugate vaccine using dynamic transmission modelling

This work is the first attempt to quantify the overall effects of a 13-valent pneumococcal conjugate vaccine (PCV13) vaccination programme in the Dutch population taking into account all the direct and indirect effects of the vaccine on invasive pneumococcal disease. Using available Dutch data, a dy...

Bibliografiset tiedot
Päätekijät:	De Cao, E, Melegaro, A, Klok, R, Postma, M
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	Public Library of Science 2014

Samankaltaisia teoksia

Optimising assessments of the epidemiological impact in The Netherlands of paediatric immunisation with 13-valent pneumococcal conjugate vaccine using dynamic transmission modelling.
Tekijä: Elisabetta De Cao, et al.
Julkaistu: (2014-01-01)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
Tekijä: V. K. Tatochenko, et al.
Julkaistu: (2012-03-01)

Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands
Tekijä: Anna M.M. van Deursen, et al.
Julkaistu: (2012-11-01)

13-valent pneumococcal conjugate vaccine in Africa
Tekijä: Robert Cohen, et al.
Julkaistu: (2017-03-01)

Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
Tekijä: Shu-ling Hoshi, et al.
Julkaistu: (2015-01-01)

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine.
Tekijä: Sweta M Patel, et al.
Julkaistu: (2022-01-01)

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine
Tekijä: Sweta M. Patel, et al.
Julkaistu: (2022-01-01)

Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children
Tekijä: Susanna Esposito, et al.
Julkaistu: (2015-01-01)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
Tekijä: James T. Peterson, et al.
Julkaistu: (2019-03-01)

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly.
Tekijä: Irina Kislaya, et al.
Julkaistu: (2019-01-01)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
Tekijä: Kristiana Alexandrova Nikolova, et al.
Julkaistu: (2021-10-01)

Efficacy of 13-valent pneumococcal conjugate vaccine in healthcare workers
Tekijä: L A Shpagina, et al.
Julkaistu: (2018-11-01)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
Tekijä: Johnna Perdrizet, et al.
Julkaistu: (2021-04-01)

Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands
Tekijä: Mirjam J. Knol, et al.
Julkaistu: (2015-11-01)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
Tekijä: Filippo Ansaldi, et al.
Julkaistu: (2020-01-01)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
Tekijä: Hye-Young Kim, et al.
Julkaistu: (2021-03-01)

The impact and cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the paediatric immunisation programme in Iceland-A population-based time series analysis.
Tekijä: Elias Eythorsson, et al.
Julkaistu: (2021-01-01)

Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus “no vaccination” and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
Tekijä: Miguel Gouveia, et al.
Julkaistu: (2019-04-01)

Clinical Efficacy of Pneumococcal Conjugate 13-valent Vaccine in Young Children
Tekijä: S. M. Kharit, et al.
Julkaistu: (2016-12-01)

Experience with 13-valent conjugated pneumococcal vaccine in HIV-infected patients
Tekijä: A. V. Zhestkov, et al.
Julkaistu: (2020-12-01)

Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children
Tekijä: Corinne Levy, et al.
Julkaistu: (2021-08-01)

Predictors to parental knowledge about childhood immunisation/EPI vaccines in two health districts in Cameroon prior to the introduction of 13-valent Pneumococcal Conjugate Vaccines (PCV-13)
Tekijä: John Njuma Libwea, et al.
Julkaistu: (2014-03-01)

Mortality of Invasive Pneumococcal Disease following Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Greenland
Tekijä: Kristiana Alexandrova Nikolova, et al.
Julkaistu: (2024-02-01)

Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia
Tekijä: Paul Turner, et al.
Julkaistu: (2015-11-01)

Pneumococcal serotypes causing pneumonia in the 13 valent pneumococcal conjugate vaccine era in Australian children
Tekijä: R. Strachan, et al.
Julkaistu: (2020-12-01)

Pneumococcal meningitis: epidemiological profile pre‐ and post‐introduction of the pneumococcal 10‐valent conjugate vaccine
Tekijä: Tatiane E. Hirose, et al.
Julkaistu: (2015-03-01)

Pneumococcal meningitis: epidemiological profile pre- and post-introduction of the pneumococcal 10-valent conjugate vaccine
Tekijä: Tatiane E. Hirose, et al.
Julkaistu: (2015-03-01)

Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
Tekijä: Sabine Haggenburg, et al.
Julkaistu: (2023-07-01)

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
Tekijä: Matthew Wasserman, et al.
Julkaistu: (2019-03-01)

The antibody response following a booster with either a 10- or 13-valent pneumococcal conjugate vaccine in toddlers primed with a 13-valent pneumococcal conjugate vaccine in early infancy.
Tekijä: Trück, J, et al.
Julkaistu: (2016)

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy
Tekijä: Hannah M. Garcia Garrido, et al.
Julkaistu: (2022-05-01)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
Tekijä: Earnshaw Stephanie R, et al.
Julkaistu: (2012-04-01)

Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
Tekijä: Min-Joo Choi, et al.
Julkaistu: (2018-08-01)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
Tekijä: Beate Schmoele-Thoma, et al.
Julkaistu: (2019-03-01)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
Tekijä: Thundon Ngamprasertchai, et al.
Julkaistu: (2023-06-01)

Immunogenicity and Safety of 13-valent Conjugated Pneumococcal Vaccine in Patients with Rheumatoid Arthritis
Tekijä: B. T. Batozhargalova, et al.
Julkaistu: (2024-03-01)

The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities
Tekijä: Yan Li, et al.
Julkaistu: (2021-11-01)

Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review
Tekijä: Yuanze Du, et al.
Julkaistu: (2023-12-01)

Results of immunoprophylaxis of HIV-infected patients with 13-valent conjugated pneumococcal vaccine
Tekijä: Alexander V. Zhestkov, et al.
Julkaistu: (2021-11-01)

Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae
Tekijä: Allison E.B. Turner, et al.
Julkaistu: (2017-03-01)